Corxel SPAC deal splits obesity pills from stroke drug ahead of CX11 Phase 3

BERKELEY HEIGHTS, NJ. The Corxel SPAC deal takes only part of Corxel public. Under an agreement with Amanat Acquisition Corp announced on Oct. 26, two oral obesity candidates will move into a Nasdaq listed company, while a stroke drug stays with a private parent. Corxel's finance chief told BioPharma Dive that investors pushed for the split. The companies expect about $377 million in gross proceeds before costs if no Amanat shareholders redeem. The deal needs a shareholder vote and is expected to close in the first half of 2027.

Why Corxel split before going public

The Corxel SPAC deal covers Corxel Pharmaceuticals Inc, the U.S. unit known as Corxel US, and only the obesity assets named in the contract. Its parent, Corxel Pharmaceuticals Limited, will receive common stock and pre-funded warrants in the combined company, the companies said. Corxel HK and JX10, a clinical-stage drug for acute ischemic stroke, stay outside the listing. Corxel acquired most rights to JX10 from Biogen in 2024, BioPharma Dive reported. The company started in 2019 as Ji Xing Pharmaceuticals and once worked on a dry eye nasal spray, which it gave up in 2024. It licensed CX11 from the Chinese developer Vincentage Pharma that same year. The public company will take a new name and ticker before closing and plans to hire a U.S.-based chief executive.

Kevin Xie, chief financial officer of Corxel US, told BioPharma Dive that backers wanted a "more dedicated focus" instead of "two different tracks." Those talks followed a $287 million Series D round raised less than a year before the merger news. "Both companies have separate development strategies and financing processes, so that's more welcome news to the investors," Xie said. The structure lets investors fund the obesity programs without also paying for stroke work. Sandy Mou, chief executive of Corxel Group, said in the release that the group's most promising pipeline deserves its own focus and resources. Our earlier deal report covered the headline terms. This follow-up looks at what the split means and what must happen before a global Phase 3 trial can start.

CX11 oral GLP 1 data so far

The CX11 oral GLP 1 candidate is a once-daily small molecule tablet, not a peptide. It is built to switch on the receptor for GLP 1, a gut peptide hormone, in the same way as non peptide pills like orforglipron. In a U.S. Phase 2 obesity trial, mean weight loss reached up to 11.5% at week 36 under the efficacy estimand, the companies said. That method estimates the effect had participants stayed on the drug as planned, so it often reads higher than an analysis that counts everyone who stopped. The release gives no placebo figure for the 11.5% result, so readers cannot yet tell how much of the loss came from the drug itself.

The release gives no placebo figure for the 11.5% result, so readers cannot yet tell how much of the loss came from the drug itself.

Stomach and gut effects were the most common problems. Across dose groups, nausea affected 33% to 34% of participants, vomiting 12% to 16%, diarrhea 4% to 12% and constipation 2% to 12%, according to the release. The companies said most cases were mild to moderate, none were severe, and most appeared while doses were being raised. About 5.0% of participants stopped treatment because of these effects. A Chinese Phase 3 trial run by Vincentage produced positive top-line results in May, BioPharma Dive reported, and a Phase 1b study is now testing higher doses. Xie said the drug has "demonstrated a really competitive profile." These claims rest on company summaries, and the release does not cite a peer-reviewed publication for either trial.

The overweight not obese pitch

The Corxel SPAC deal arrives after approved pills have already reached patients. Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo came to market first, BioPharma Dive noted. Xie argued that CX11 could still appeal to people who are overweight but not obese and need to lose 5% to 10% of their weight. The company also pitches it for people who do not stay on injectable GLP 1 drugs. The National Institute of Diabetes and Digestive and Kidney Diseases estimates that nearly 1 in 3 adults in the United States, or 30.7%, have overweight, based on 2017 to 2018 survey data for people aged 20 and older. That makes overweight adults a large group, but its size says nothing about whether CX11 will help them.

Corxel's second asset follows the same oral approach. CX12 is a preclinical small molecule meant to work as an oral amylin agonist, and the company is still comparing several lead candidates. It aims to file an investigational new drug application in the first half of 2027, the release said. Amylin is a peptide hormone released alongside insulin, and the amylin drugs furthest along, such as petrelintide from Zealand Pharma and Roche, are injected peptides. A pill would be a different bet, and no human data exist for CX12 yet. For readers judging the pitch, a useful test is whether later trials report placebo-adjusted results in people with overweight alone, using the checks in our guide to reading weight loss trial headlines.

Money and milestones before Phase 3

Amanat Acquisition Corp, a blank check company listed on Nasdaq, holds about $75 million in its trust account, according to the release. A concurrent private placement adds about $300 million from investors including RTW Investments, New Enterprise Associates, SR One and RA Capital Management. The $377 million total assumes no redemptions, and SPAC shareholders can ask for their cash back before closing. Placement investors may also cut their commitments by buying Amanat shares in the market and not redeeming them, with a matching cut in what they pay. That clause can change the cash mix, so the final amount may differ. The companies said net proceeds should fund operations through 2029, including global Phase 3 work for CX11. That runway is a company forecast, not a result.

Several steps stand between the signing and a global trial. Amanat must file a Form S-4 registration statement with the Securities and Exchange Commission, win a shareholder vote and meet Nasdaq listing rules. After an End-of-Phase 2 meeting, Corxel US says it agreed with the FDA on key parts of the CX11 regulatory path and Phase 3 design, and that account comes from the company alone. BioPharma Dive reported that an international Phase 3 study could begin as early as the first quarter of 2027. Results from the higher dose Phase 1b study are also due in the first half of 2027. Details on deal conditions sit in the joint merger announcement, and the full agreement will appear in an SEC filing.

Conclusion

The Corxel SPAC deal separates a private stroke business from a public company built on two oral obesity candidates. CX11 has company-reported Phase 2 and Chinese Phase 3 results, but the merger release gives no placebo figure, and CX12 has no human data. The next checkpoints are the Amanat vote, higher dose results and a Phase 3 start, all expected in 2027. Until then, the efficacy and cash figures are company statements that outside reviewers have not tested.